Citations

Clear

439 citation(s) found for "Stone, M".

Reply
Khosroshahi, Arezou , Cheryk, Lynn A., Bloch, Donald B. , Stone, John H., Stone, John H.

Mayo Clinic

Arthritis & Rheumatology | June 25, 2014 | Volume: 66 | Issue: 11 | Pages: 3247-3248

10.1002/art.38751 | PMID 24965491 Get It

Preventive Measures for Patients at Risk for Amputation From Diabetes and Peripheral Arterial Disease
Goodney, Philip P. , McClurg, Asha B. , Stone, David H. , DeMartino, Randall R. , Spangler, Emily L. , Brooke, Benjamin S. , Nolan, Brian W.

Mayo Clinic

Diabetes Care | May 22, 2014 | Volume: 37 | Issue: 6 | Pages: e139-e140

10.2337/dc14-0034 | PMID 24855171 Get It

Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition
Knutson, Keith L. , Stone, Brad, Reiman, Jennifer M. , Behrens, Marshall D., Prosperi, Christine , Gad, Ekram, Smorlesi, Arianna, Knutson, Keith L. , Lu, Hailing , Disis, Mary Lenora

Mayo Clinic

The Journal of Immunology | April 24, 2014 | Volume: 177 | Issue: 3 | Pages: 1526-1533

10.4049/jimmunol.177.3.1526 | PMID 16849459 Get It

Abstract Tumors evade both natural and pharmacologically induced (e.g., vaccines) immunity by a variety of mechanisms, including induction of tolerance and immunoediting. Immunoediting results in reshaping the immunogenicity of the tumor, which can be accompanied by loss of Ag expression and MHC molecules. In this study, we evaluated immunoediting in the neu-transgenic mouse model of breast cancer. A tumor cell line that retained expression of rat neu was generated from a spontaneous tumor of the neu-transgenic mouse and, when injected into the non-transgenic parental FVB/N mouse, resulted in the development of a strong immune response, initial rejection, and ultimately the emergence of neu Ag-loss variants. Morphologic and microarray data revealed that the immunoedited tumor cells underwent epithelial to mesenchymal transition accompanied by an up-regulation of invasion factors and increased invasiveness characteristic of mesenchymal tumor cells. These results suggest that immunoediting of tumor results in cellular reprogramming may be accompanied by alterations in tumor characteristics including increased invasive potential. Understanding the mechanisms by which tumors are immunoedited will likely lead to a better understanding of how tumors evade immune detection.
Conversations in Cardiology
Applegate, Robert J., Bell, Malcolm R. , Brilakis, Emmanouil S. , Bach, Richard G. , Kaul, Prashant , Klein, Lloyd W. , Krucoff, Mitchell W., Stone, Gregg W. , Kern, Morton J. , Butman, Samuel M. , Moore, Joseph Allen , Price, Matthew J. , Rao, Sunil V. , Uretsky, Barry F. , Brilakis, Emmanouil S

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 13, 2013 | Volume: 83 | Issue: 5 | Pages: 748-752

10.1002/ccd.25319 | PMID 24395180 Get It

Bridging for antiplatelet therapy remains a subject of debate with data favoring GP blockers but at a risk of bleeding. This Conversation in Cardiology addresses a key and often asked question about use of alternatives to P2Y12 agents in patients requiring surgery within 6 months after drug eluting stent implantation. © 2013 Wiley Periodicals, Inc.
Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's)
Tómasson, Gunnar , Davis, John C. , Hoffman, Gary S., McCune, W. Joseph, Clair, E. William St. , Stone, John H. , Specks, Ulrich , Spiera, Robert , Merkel, Peter A.

Mayo Clinic

Arthritis & Rheumatology | October 31, 2013 | Volume: 66 | Issue: 2 | Pages: 428-432

10.1002/art.38248 | PMID 24504815 Get It

ObjectiveTo 1) describe the distribution of patient global assessment (PtGA) scores of disease activity in patients with granulomatosis with polyangiitis (GPA; Wegener's), 2) explore the discordance between PtGA scores and physician global assessment (PhGA) scores of disease activity, and 3) explore whether PtGA scores during disease remission are associated with future disease relapse.MethodsData from the Wegener's Granulomatosis Etanercept Trial (WGET) were used. PtGA and PhGA scores were assessed on 100‐mm visual analog scales (VAS). Presence of active disease was determined using the Birmingham Vasculitis Activity Score for WG (BVAS/WG), and remission was defined as a BVAS/WG score of 0. Disease relapse was defined as a BVAS/WG score of >0 after remission had been achieved. Discordance between PtGA and PhGA scores was defined as a difference of ≥20 points between the two measures. Mixed linear models were used in longitudinal analysis of PtGA scores.ResultsData were obtained from 180 patients in the WGET cohort, seen at a total of 1,719 study visits. The mean ± SD PtGA and PhGA disease activity scores (on 100‐mm VAS) at baseline were 64.2 ± 27.4 and 55.5 ± 23.4, respectively. PtGA–PhGA discordance occurred in 53% of patients at baseline, and this was inversely associated with newly diagnosed disease (as opposed to relapsing disease) at baseline (odds ratio 0.37, 95% confidence interval [95% CI] 0.20–0.68) but not with age, sex, or presence of renal or pulmonary disease. Patients were in disease remission during 62% of the study visits. The mean PtGA score during visits immediately prior to relapse was 4.52 points higher (95% CI 0.66–8.4) than that at other remission visits (P = 0.03).ConclusionPtGA–PhGA discordance is common in GPA. A rise in the PtGA disease activity score during times defined by physicians as periods of remission is associated with subsequent occurrence of disease relapse. These findings support the addition of PtGA as an outcome measure for GPA.
Robot-Assisted Radical Nephrectomy and Inferior Vena Cava Tumor Thrombectomy
Grimsby, Gwen M. , Stone, William M., Castle, Erik P.

Mayo Clinic

Videourology™ | July 31, 2013 | Volume: 27 | Issue: 5 | Pages: No page available

10.1089/vid.2013.0019 Get It

SAGE-Journals-Accessible-Video-Player 10.1089/vid.2013.0019.M1 sj-vid-1-vid-10.1089_vid.2013.0019
Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (SCAI)
Moussa, Issam , Klein, Lloyd W. , Shah, Binita , Mack, Michael J. , Brilakis, Emmanouil S. , Zoghbi, Gilbert J., Holper, Elizabeth M. , Stone, Gregg W. , Moussa, Issam D, Mehran, Roxana , Reilly, John P. , Brilakis, Emmanouil S , Shah, Binita

Mayo Clinic

Catheterization and Cardiovascular Interventions | July 25, 2013 | Volume: 83 | Issue: 1 | Pages: 27-36

10.1002/ccd.25135 | PMID 23894025 Get It

Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)‐related MI (type 4a) and coronary artery bypass grafting (CABG)‐related MI (type 5) which are of uncertain prognostic importance. In addition, for both MI types cTn is recommended as the biomarker of choice, the prognostic significance of which is less well validated than CK‐MB. Widespread adoption of a MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence. Rather than employing an MI definition sensitive for small degrees of myonecrosis (the occurrence of which, based on contemporary large‐scale studies, are unlikely to have important clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been strongly linked to subsequent adverse events in clinical studies be used to define a “clinically relevant MI.” The present document introduces a new definition for "clinically relevant MI" after coronary revascularization (PCI or CABG) which is applicable for use in clinical trials, patient care, and quality outcomes assessment. © 2013 Wiley Periodicals, Inc.
Three-Dimensional Dual-Energy Computed Tomography for Enhancing Stone/Stent Contrasting and Stone Visualization in Urolithiasis
Ibrahim, El-Sayed H. , Haley, William E. , Jepperson, Maria A., Thiel, David D. , Wehle, Michael J., Cernigliaro, Joseph G.

Mayo Clinic

Case Reports in Urology | July 17, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-4

10.1155/2013/646087 | PMID 23956922 Get It

The use of dual-energy computed tomography (DECT) for evaluating urinary calculi has been appreciated due to the modality’s capability of differentiating between uric acid (UA) and non-UA stones, which are color coded based on a postprocessing algorithm. No other imaging modality or laboratory test is able to identify the stone composition without first attaining the stone material. Knowledge of the stone composition is clinically significant since UA calculi may be treated medically whereas non-UA calculi may require surgical removal. Regardless of the stone type, ureteral stents are often placed to prevent or treat obstruction. Recent work has demonstrated that commonly used stents are also colored based on their dual energy characteristics and may thereby either improve or obscure the identification of adjacent calculi. Herein, we report the case of a 65-year-old man who underwent percutaneous nephrolithotomy of a large staghorn stone with subsequent significant residual stone fragments noted on a follow-up scan. By using three-dimensional DECT and taking advantage of color contrasting, the stone composition, burden, shape, and boundary were clearly depicted apart from the adjacent stent, resulting in successful medical treatment and obviating the need for further surgical intervention.
Two Birds With One Stone: Octreotide Treatment for Acromegaly and Breast Cancer
Chae, Young Kwang , Katz, Ruth L., Chávez‐MacGregor, Mariana , Haluska, Paul , Melhem‐Bertrandt, Amal , Hu, Mimi I. , Meric‐Bernstam, Funda , González-Angulo, Ana M. , Chavez-MacGregor, Mariana

Mayo Clinic

Journal of Clinical Oncology | June 25, 2013 | Volume: 31 | Issue: 23 | Pages: e398-e400

10.1200/jco.2012.46.6383 | PMID 23796991 Get It

Clinical Outcomes of Remission Induction Therapy for Severe Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Miloslavsky, Eli M. , Seo, Philip , Langford, Carol A. , Hoffman, Gary S., Kallenberg, Cees G. M., Clair, E. William St. , Tchao, Nadia K., Viviano, Lisa, Ding, Linna , Sejismundo, Lourdes P., Mieras, Kathleen, Iklé, David , Jepson, Brett , Mueller, Mark, Brunetta, P., Allen, Nancy B., Keogh, Karina A., Peikert, Tobias, Stegeman, Coen A. , Ytterberg, Steven R. , Stone, John H., Brunetta, Paul , Specks, Ulrich , Merkel, Peter A. , Spiera, Robert , Fervenza, Fernando C. , Geetha, Duvuru , Kissin, Eugene Y. , Monach, Paul A.

Mayo Clinic

Arthritis & Rheumatism | June 10, 2013 | Volume: 65 | Issue: 9 | Pages: 2441-2449

10.1002/art.38044 | PMID 23754238 Get It

ObjectiveTo evaluate the reasons that complete remission is not achieved or maintained with original treatment in some patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) treated with rituximab (RTX) or with cyclophosphamide/azathioprine (CYC/AZA).MethodsThe Rituximab in AAV trial was a randomized, double‐blind, placebo‐controlled trial comparing the rate of remission induction among patients treated with RTX (n = 99) and patients treated with CYC followed by AZA (n = 98). Glucocorticoids were tapered over a period of 5 months. The primary outcome measure was lack of disease activity without glucocorticoid treatment at 6 months. To determine the most important reason for failure to achieve the primary outcome, 7 hierarchical categories of reasons were defined retrospectively (uncontrolled disease, adverse event leading to therapy discontinuation, severe flare, limited flare, Birmingham Vasculitis Activity Score for Wegener's Granulomatosis >0, prednisone treatment at any dosage, and other).ResultsAlthough remission (lack of disease activity) was achieved in 170 of the 197 patients (86%) in the first 6 months, the primary outcome measure was not achieved in 42%. There were 3 deaths. Twenty‐four percent of the patients failed to achieve the primary end point due to active disease: 10 (5%) experienced uncontrolled disease in the first month and 37 (19%) experienced flares after initial improvement. In the majority of such patients, treatment with blinded crossover or according to best medical judgment led to disease control. Ninety‐one percent of patients who had uncontrolled disease or experienced a severe flare had proteinase 3 (PR3)–ANCA. When patients with uncontrolled disease were excluded from analysis, those who were PR3‐ANCA positive were found to experience fewer flares when treated with RTX compared to CYC/AZA (8 of 59 [14%] versus 20 of 62 [32%]; P = 0.02). Neither ANCA titers nor B cell counts predicted disease flare.ConclusionCurrent treatment regimens are largely successful in controlling AAV, but in approximately one‐fourth of patients, active disease persists or recurs in the first 6 months despite treatment. PR3‐ANCA positivity is a risk factor for recurrence or persistence of severe disease. ANCA titers and B cell detectability are poor predictors of both disease relapse and disease quiescence in the first 6 months.